House committee Recommends Budget Increases for NIH, NCI

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 9
Volume 4
Issue 9

WASHINGTON--In a surprise move, the House Labor, HHS and Education Subcommittee of the House Appropriations Committee voted to increase NIH funding by about $642 million for FY 1996. NCI's 1996 budget of $2.25 billion represents a $31 million increase over the current budget.

WASHINGTON--In a surprise move, the House Labor, HHS and EducationSubcommittee of the House Appropriations Committee voted to increaseNIH funding by about $642 million for FY 1996. NCI's 1996 budgetof $2.25 billion represents a $31 million increase over the currentbudget.

To support these increases, the subcommittee recommended cutsin other health, labor and education programs.

The Appropriations Committee believes that NIH should allocatefunds on the basis of scientific opportunity; thus there are noearmarks by disease or research mechanism, and no separate fundingfor the Office of AIDS Research. No further funds are providedto support the NCI study of tobacco industry campaign contributionsto state legislators.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content